Rep. David J. Taylor (R-OH) Buys Amgen (AMGN) Stock
House Republican David J. Taylor has purchased shares of Amgen Inc. valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. David J. Taylor (R-OH) bought between $1,001 and $15,000 of Amgen Inc. ($AMGN) stock on September 22, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 1, 2026.
Since the trade, $AMGN is up 3.3% after 1 week and up 5.4% to date (from the $410.24 close on Sep 22, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. David J. Taylor (R)
- Status:
- Member — House
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 1, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Amgen Inc. ($AMGN) | Buy | Sep 22, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
AMGN
Amgen Inc.
Key Points
- David J. Taylor acquired Amgen Inc. shares valued between $1,001 and $15,000 on September 22, 2026.
- Amgen's stock is currently trading around $433.04, near its 52-week high of $447.03.
- The company's P/E ratio stands at 26.96, reflecting its valuation in the healthcare sector.
Get $AMGN trade alerts by text
We text you when insiders, Congress or big funds trade $AMGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Amgen Inc. alert may contain errors. Disclosures
House Republican David J. Taylor bought shares of Amgen Inc. (AMGN) valued between $1,001 and $15,000 on September 22, 2026. This transaction is reported in his periodic transaction report filed under the STOCK Act, which shows trades made by politicians. The reported share price at that time was about $433.04.
David J. Taylor vs. the S&P 500
Hypothetical returns from David J. Taylor's disclosed trades, not real profit or advice. How we model this.
Inside David J. Taylor's Trade
Taylor's recent purchase adds to his list of stock investments, reflecting a continued interest in the healthcare sector, particularly in companies like Amgen that focus on drug manufacturing. The exact number of shares purchased was not disclosed in the filing.
Other Institutional Activity in Amgen
Several institutional investors have maintained significant positions in Amgen Inc. Blackrock Inc. holds 49,362,016 shares, worth about $21.36 billion after increasing its stake by 2,260,856 shares, a 4.8% change. Vanguard Capital Management LLC also retains a large position with 35,250,101 shares valued at approximately $15.25 billion, with a smaller increase of 234,604 shares or 0.7%. Meanwhile, State Street Corporation holds 30,560,537 shares, and Capital World Investors decreased its position slightly, selling 213,811 shares for a total of 29,075,329 shares.
Amgen Inc. Stock Up 1.6%
Amgen's shares are currently trading at $433.04, close to its 52-week high of $447.03. The stock has shown strong performance lately, having gained momentum, and is well above its 200-day moving average of $368.38. This level of trading may indicate investor confidence in the company's future prospects.
Recent Earnings
In its latest earnings report, Amgen generated revenue of approximately $38.1 billion, reflecting a growth rate of about 9.5%. The company's EPS was reported at $16.10, with a net margin of 22.95%, showcasing its profitability. Investors should look out for the next earnings announcement scheduled for November 3, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 6.1%. Revenue missed estimates by 1.5%.
-
Profit surprise
EBITDA missed by 45 percent. Operating income missed by 28 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 target raise, 2 target cuts.
-
Earnings quality
Gross margin up 4.6 points. Operating margin up 16.5 points. Positive free cash flow.
Earnings Call Summary
Amgen had a strong first quarter with earnings per share of 5.15 dollars beating expectations of 4.73 dollars. Six key medicines grew sales by 24 percent year over year and now make up 70 percent of total sales. The obesity drug Meritide is advancing well in late-stage testing with new studies showing better tolerance when patients take it less frequently, potentially every eight to twelve weeks instead of weekly injections.
Guidance Amgen raised its 2026 outlook to revenue between 37.1 billion and 38.5 billion dollars, and earnings per share between 21.70 and 23.10 dollars. The company expects its fast-growing medicines like Repatha and Evenity to offset patent losses. Management said capital spending will remain at about 2.6 billion dollars to scale manufacturing for new drug launches.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Analysts Set New Price Targets
On October 13, Guggenheim maintained a 'Neutral' rating on Amgen with a price target of $378, down from $388. BMO Capital also maintained a 'Market Perform' rating with a target of $415, lowered from $450. Meanwhile, Wells Fargo held its 'Equal-Weight' rating with a target of $430, down from $435. UBS rated the stock as 'Buy' and raised its target from $430 to $470, while RBC Capital maintained an 'Outperform' rating and raised its target from $400 to $430. The consensus rating remains a 'Hold' with a mean target price of approximately $394.98 based on 29 analyst opinions.
About Amgen
Amgen Inc. is a leading biotechnology company based in Thousand Oaks, California. It focuses on discovering, developing, manufacturing, and delivering human therapeutics worldwide. This recent investment by David J. Taylor may reflect ongoing interest in companies that contribute significantly to healthcare solutions, which can be particularly relevant for his constituents.
Bottom Line
David J. Taylor's recent purchase of Amgen shares highlights his ongoing engagement in the healthcare sector. As Amgen approaches its next earnings date, investors will be watching for further developments, including additional filings and analyst updates. The 13F filing reflects holdings as of the reporting period and may not represent current positions.
Related Filing Alerts
Source: David J. Taylor's STOCK Act disclosure on $AMGN (Sep 22, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts